Kingswood Capital Partners, LLC

Rodman & Renshaw's $8 price target reflects its valuation of Quantum Biopharma's overall development pipeline, anchored by the newly cleared Phase II program.

This initiation follows earlier unpaid coverage from Kingswood Capital Partners, which set a $45 price target in September 2025, based on a discounted cash flow model, assuming successful Phase 2 and Phase 3 trials, and a 2029 commercial launch.

New analyst coverage matters for a clinical-stage biopharmaceutical company because it signals that outside experts, with no obligation to be optimistic, see enough evidence in the data to justify a formal recommendation.

For a small-cap company preparing to enter a pivotal trial, that kind of third-party validation can help build the visibility and credibility needed to support the stock through a long and expensive testing process.